Strategic Partnership to Advance Gene Editing Technologies in
Biomedical Applications
SHANGHAI, June 18,
2024 /PRNewswire/ -- YolTech, a clinical-stage
biopharmaceutical company specializing in mRNA-LNP delivery for
in vivo gene editing therapies, has partnered with KACTUS, a
leading developer serving the biopharmaceutical industry, to
advance the commercialization of YolTech's proprietary DNA editor,
YolCas12TM, in Greater
China. Under this agreement, KACTUS gains exclusive rights
for the production and sale of YolCas12TM.
YolCas12TM represents a breakthrough in
molecular-level targeted modifications, offering unparalleled
accuracy and efficiency. This technology holds tremendous potential
for diverse applications, including gene therapy and biomedical
research which has been validated by multiple collaborative
companies. Currently, TolTech has applied this editor to enter the
clinical trial stage.
"We are excited to announce this collaboration with KACTUS,
which underscores our leadership in genetic innovation," said Dr.
Yuxuan Wu, Founder and CEO of
YolTech. "This milestone reflects our commitment to advancing in
vivo gene editing and our dedication to improving patient
outcomes."
Mr. Gang Wang, Founder and CEO of KACTUS, added, " We are
excited to integrate YolTech's leading gene editing tools with
KACTUS's commercial capabilities, enhancing accessibility to
advanced therapies."
About YolTech
YolTech Therapeutics is a leading clinical-stage genome editing
company focused on developing potentially curative therapies
leveraging CRISPR-based technologies. The company has built a
leading high-throughput evolution platform and innovative LNP
delivery system. YolTech possesses a strong capability for novel
Cas and base editor discovery, as well as exceptional in-house LNP
production capacity for GMP manufacturing. It holds independent
intellectual property rights and core patent protection globally.
The company has created a pipeline of 10 genetic medicines focusing
on cardiovascular diseases, metabolic diseases, infectious
diseases, as well as more common and rare diseases. Clinical trial
clearance has been received for its leading asset in March 2024.
About KACTUS
KACTUS is a biotech company that specializes in providing
high-purity, high-activity, recombinant protein and enzyme products
for a range of fields including antibody drug discovery,
immunotherapy, gene editing, and mRNA therapeutics. The mission is
to provide first-to-market recombinant protein and enzymes to
accelerate novel biopharma and diagnostic breakthroughs.
View original
content:https://www.prnewswire.com/news-releases/yoltech-and-kactus-join-forces-to-propel-innovative-dna-editing-system-in-greater-china-302175793.html
SOURCE YolTech Therapeutics